INTRAHEPATIC CHOLANGIOCARCINOMA
Clinical trials for INTRAHEPATIC CHOLANGIOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new INTRAHEPATIC CHOLANGIOCARCINOMA trials appear
Sign up with your email to follow new studies for INTRAHEPATIC CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted drug shows promise for hard-to-treat bile duct cancer
Disease control CompletedThis study tested a new drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block FGFR2, which can help slow or shrink tumors. The goal was to find the best dose and see how well it…
Matched conditions: INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated May 17, 2026 03:13 UTC
-
New combo shows promise for Tough-to-Treat bile duct cancer
Disease control CompletedThis study tested a three-part treatment for people with advanced bile duct cancer that had worsened after standard chemotherapy. The treatment combined a targeted drug (apatinib), an immunotherapy (PD-1 antibody), and a procedure that delivers chemotherapy directly to the liver …
Matched conditions: INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: Sichuan Cancer Hospital and Research Institute • Aim: Disease control
Last updated May 17, 2026 03:10 UTC
-
Bubble burst: ultrasound may boost bile duct cancer radiotherapy
Diagnosis CompletedThis study tested whether a special ultrasound using gas microbubbles can predict how well bile duct cancer responds to targeted radiotherapy. It also explored if popping those microbubbles during imaging could make the radiation more effective. Sixteen adults with untreated bile…
Matched conditions: INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: Thomas Jefferson University • Aim: Diagnosis
Last updated May 14, 2026 12:05 UTC